Profitability Ratios
| Ratio |
Value |
| GP Margin |
88.1% |
| EBIT Margin |
-94.6% |
| EBITDA Margin |
-85.4% |
| Operating Margin |
-94.6% |
| Pretax Margin |
-113.8% |
| Cont. Ops Margin |
-113.8% |
| Net Margin |
-113.8% |
| Bottom Line Margin |
-113.8% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.38 |
| Quick Ratio |
2.38 |
| Solvency Ratio |
-0.509 |
| Cash Ratio |
0.29 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.21 |
| Forward PEG |
0.21 |
| Price/Book |
7.23 |
| Price/Sales |
4.36 |
| Price/FCF |
-5.88 |
| Price/Op Cash Flow |
-5.99 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.5751 |
| Debt/Equity |
2.5359 |
| Debt/Capital |
0.7172 |
| Long-Term Debt/Capital |
0.5893 |
| Financial Leverage |
4.41 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.01 |
| Operating Cash Flow Ratio |
-1.050 |
| Operating Cash Flow/Sales |
-72.7% |
| Free Cash Flow/Operating Cash Flow |
101.9% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-1.57 |
| Interest Coverage |
-3.5815 |
| Short-Term Operating Cash Flow Coverage |
-2.59 |
| Operating Cash Flow Coverage |
-0.48 |
| Capital Expenditure Coverage |
-51.35 |
| Dividend + Capital Expenditure Coverage |
-51.35 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
3.30 |
| EPS |
-3.759 |
| Debt/Share |
5.9241 |
| Cash/Share |
4.46 |
| Book Value/Share |
1.99 |
| Tangible BV/Share |
1.99 |
| Equity/Share |
1.99 |
| Operating Cash Flow/Share |
-2.404 |
| Capital Expenditure/Share |
0.047 |
| FCF/Share |
-2.450 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
1.203 |
| Price/Fair Value |
7.23 |
| Debt/Market Cap |
0.2630 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-6.65 |
RGNX - REGENXBIO Inc.